AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...

We recently compiled a list of the 11 Most Expensive Stocks Insiders Are Buying Recently. In this article, we are going to ...

MINNEAPOLIS/ST. PAUL (3/04/2025) — Making decisions in uncertain situations is part of daily life. New research from the University of Minnesota Medical School has uncovered that anxiety and apathy — ...

Equities research analysts at Brookline Capital Management issued their Q2 2025 EPS estimates for shares of C4 Therapeutics ...

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...

Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...

A high-fish diet is linked to less MS disability progression over time, which could be explained by high levels of omega 3 ...

Paramagnetic rim lesions help confirm multiple sclerosis diagnoses and may have prognostic value. New evidence of an immune ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

Hospital-based care for hallucinogen use is associated with increased mortality, according to a study published online March ...